KR850003503A - 갱글리오사이드 및 그 유도체의 흡입투여 키트와 이에 적합한 약제 조성물 - Google Patents
갱글리오사이드 및 그 유도체의 흡입투여 키트와 이에 적합한 약제 조성물 Download PDFInfo
- Publication number
- KR850003503A KR850003503A KR1019840006985A KR840006985A KR850003503A KR 850003503 A KR850003503 A KR 850003503A KR 1019840006985 A KR1019840006985 A KR 1019840006985A KR 840006985 A KR840006985 A KR 840006985A KR 850003503 A KR850003503 A KR 850003503A
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- acid
- kit
- ganglioside
- site
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims 12
- 150000002270 gangliosides Chemical class 0.000 title claims 7
- 239000002253 acid Substances 0.000 claims 11
- 229940124630 bronchodilator Drugs 0.000 claims 6
- 150000001720 carbohydrates Chemical group 0.000 claims 6
- 150000002148 esters Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000007921 spray Substances 0.000 claims 5
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical group CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000686 lactone group Chemical group 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 125000003047 N-acetyl group Chemical group 0.000 claims 2
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 2
- 235000014633 carbohydrates Nutrition 0.000 claims 2
- 229940106189 ceramide Drugs 0.000 claims 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- -1 ganglioside compound Chemical class 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
- C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (14)
- 약제 조성물을 흡입투여시키기 위한 기트로서, 흡입투여용 스프레이장치와, 투여되는 약제조성물로는 적어도 하나의 갱글리오사이드 화합물 또는 약리학상 허용되는 염, 또는 적어도 하나의 갱글리오사이드 분자내 에스텔 유도체 또는 약리학상 허용되는 염, 또는 그들의 혼합물과, 약리학상 허용되는 담체 또는 희석제를 함유하되 상기의 갱글리오 사이드의 분자내 에스텔 유도체는, (1) 카보하이드레이트부분 적어도 하나의 세라미드 및 적어도 하나의 산부위, (2) 적어도 하나의 N-아세틸 가락 토사민이나 하나의 글르코오스 또는 가락토오스 부위를 함유한 상기의 카보하이드레이트 부분, (3) 적어도 하나의 N-아세틸 뉴라민산 또는 N-글루코틸 뉴라민산을 함유한 상기의 산부위 및, (4) 상기의 카보하이드레이트중 하나의 하이드록실 그룹 또는 상기의 산부위중 하나와 에스텔 결합을 하여 락톤환을 형성하는 상기의 산부위중 적어도 하나의 카복실그룹으로 이루어진 것임을 특징으로 하는 키트.
- 제1항에 있어서, 스프레이장치는 압력식 스프레이 병으로 이루어진 것임을 특징으로 하는 키트.
- 제1항에 있어서, 약제조성물은 기관지 확장제를 함유한 것임을 특징으로 하는 키트.
- 제3항에 있어서, 기관지 확장제는 이소프레날린염을 특징으로 하는 키트.
- 제3항에 있어서, 기관지 확장제는 아드레날린임을 특징으로 하는 키트.
- 제1항에 있어서, 약제조성물은 분무화 분말의 형태인 것임을 특징으로 하는 키트.
- 제1항에 있어서, 약제조성물은 분무 액화 추진 현탁액 또는 용액의 형태인 것임을 특징으로 하는 키트.
- 제1항에 있어서, 갱글리오사이드의 분자내 에스텔유도체에서의 산부위중 카복실 그룹은 각각 상기의 카복실 그룹중 하나의 하이드록실 그룹 또는 상기 산부위의 하나와 에스텔 결합하여 락톤환을 형성함을 특징으로 하는 키트.
- 제1항에 있어서, 약제조성물은 상기의 스프레이 장치중에 함유되어 있음을 특징으로 하는 키트.
- 적어도 하나의 갱글리오사이드 화합물 또는 약리학상 허용되는 염, 또는 적어도 하나의 갱글리오사이드 분자내 에스텔 유도체 또는 약리학상 허용되는 염, 또는 그들의 혼합물과 기관지 확장제 및 약리학상 허용되는 부형제 또는 희석제로 구성되어지되 상기 갱글리오사이드의 분자내 유도체는 (1) 카보하이드레이트부분 적어도 하나의 세라미드 및 적어도 하나의 산부위, (2) 적어도 하나의 N-아세틸 가락토사민이나 하나의 글루코오스 또는 각락토오스 부위를 함유한 상기의 카보하이드레이트 부분, (3) 적어도 하나의 N-아세틸뉴라민산 또는 N-클루코릴뉴라민산을 함유한 상기의 산부위 및, (4) 상기의 카보하이드레이트중 하나의 하이드록실 그룹 또는 상기의 산부위중 하나와 에스텔 결합을 하여 락톤환을 형성하는 상기의 산부위중 적어도 하나의 카복실 그룹으로 이루어진 것임을 특징으로 하는 약제 조성물.
- 제10항에 있어서, 기관지 확장제는 이소프레날린 설페이트임을 특징으로 하는 약제조성물.
- 제10항에 있어서, 기관지 확장제는 아드레날린임을 특징으로 하는 약제조성물.
- 제10항에 있어서, 부형제는 락토스임을 특징으로 하는 약제 조성물.
- 제10항에 있어서, 갱글리오사이드의 분자내 에스텔 유도체에서의 산부위중 카복실그룹은 각각 상기의 카복시하이레이트중 하나의 하이드록실 그룹 또는 상기의 산부위중 하나와 에스텔 결합하여 락톤환을 형성함을 특징으로 하는 약제조성물.※ 참고사항：최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT49288A/83 | 1983-11-08 | ||
| IT8349288A IT1212896B (it) | 1983-11-08 | 1983-11-08 | Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR850003503A true KR850003503A (ko) | 1985-06-20 |
Family
ID=11270228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019840006985A KR850003503A (ko) | 1983-11-08 | 1984-11-08 | 갱글리오사이드 및 그 유도체의 흡입투여 키트와 이에 적합한 약제 조성물 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4639437A (ko) |
| EP (1) | EP0145209B1 (ko) |
| JP (1) | JPS60132920A (ko) |
| KR (1) | KR850003503A (ko) |
| AT (1) | ATE47035T1 (ko) |
| AU (1) | AU569920B2 (ko) |
| BE (1) | BE900994A (ko) |
| CH (1) | CH662278A5 (ko) |
| DE (1) | DE3480053D1 (ko) |
| DK (1) | DK160129C (ko) |
| ES (1) | ES8608532A1 (ko) |
| FR (1) | FR2554346B1 (ko) |
| GR (1) | GR80853B (ko) |
| IL (1) | IL73292A (ko) |
| IN (1) | IN163563B (ko) |
| IT (1) | IT1212896B (ko) |
| LU (1) | LU85633A1 (ko) |
| MX (1) | MX163574B (ko) |
| NO (1) | NO844443L (ko) |
| NZ (1) | NZ209974A (ko) |
| PT (1) | PT79466B (ko) |
| ZA (1) | ZA848541B (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1177863B (it) * | 1984-07-03 | 1987-08-26 | Fidia Farmaceutici | Una miscela gangliosidica come agente terapeutico capare di eliminare il dolore nele neuropatie periferiche |
| JPS6368526A (ja) * | 1986-09-11 | 1988-03-28 | Mect Corp | シアリルグリセライドからなる神経障害疾患治療剤 |
| US4816450A (en) * | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
| US4937232A (en) * | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
| IT1212041B (it) * | 1987-11-02 | 1989-11-08 | Fidia Farmaceutici | Gangliosidi esteri interni come agenti terapeutici capaci di eliminare il dolore nelle neuropatie periferiche |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US6407061B1 (en) * | 1989-12-05 | 2002-06-18 | Chiron Corporation | Method for administering insulin-like growth factor to the brain |
| US5624898A (en) | 1989-12-05 | 1997-04-29 | Ramsey Foundation | Method for administering neurologic agents to the brain |
| AU6909091A (en) * | 1989-12-05 | 1991-06-26 | Ramsey Foundation | Neurologic agents for nasal administration to the brain |
| IT1249034B (it) * | 1990-06-29 | 1995-02-11 | Fidia Spa | Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi |
| WO1992017189A1 (en) * | 1991-03-29 | 1992-10-15 | The Regents Of The University Of California | Gangliosides with immunosuppressive activity |
| WO1993002686A1 (en) * | 1991-07-31 | 1993-02-18 | The Regents Of The University Of California | Gangliosides with immunosuppressive ceramide moieties |
| US5567684A (en) * | 1994-09-14 | 1996-10-22 | The Regents Of The University Of California | Synthetic ganglioside derivatives |
| US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
| MXPA04001831A (es) | 2001-08-29 | 2004-07-08 | Neose Technologies Inc | Nuevos derivados sinteticos de gangliosidos y composiciones de los mismos. |
| US7888331B2 (en) | 2003-03-06 | 2011-02-15 | Seneb Biosciences, Inc. | Ganglioside compositions and methods of use |
| CU23317A1 (es) | 2005-07-22 | 2008-10-22 | Ct De Investigacia N Y Desarro | Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central |
| US20120035120A1 (en) | 2009-03-25 | 2012-02-09 | Seneb Biosciences, Inc. | Glycolipids as treatment for disease |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL262354A (ko) * | 1960-03-17 | |||
| US3282781A (en) * | 1960-11-25 | 1966-11-01 | Merck & Co Inc | Inhalant compositions |
| US4094968A (en) * | 1972-09-06 | 1978-06-13 | Burroughs Wellcome Co. | Treatment for allergy and method of composition thereof |
| GB1571629A (en) * | 1977-11-30 | 1980-07-16 | Fisons Ltd | Pharmaceutical compositions containing beclomethasone dipropionate |
| US4476119A (en) * | 1981-08-04 | 1984-10-09 | Fidia S.P.A. | Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions |
-
1983
- 1983-11-08 IT IT8349288A patent/IT1212896B/it active
-
1984
- 1984-04-12 US US06/599,340 patent/US4639437A/en not_active Expired - Fee Related
- 1984-10-23 IL IL73292A patent/IL73292A/xx unknown
- 1984-10-23 DK DK505584A patent/DK160129C/da not_active IP Right Cessation
- 1984-10-24 NZ NZ209974A patent/NZ209974A/en unknown
- 1984-10-26 EP EP84307403A patent/EP0145209B1/en not_active Expired
- 1984-10-26 AT AT84307403T patent/ATE47035T1/de not_active IP Right Cessation
- 1984-10-26 DE DE8484307403T patent/DE3480053D1/de not_active Expired
- 1984-10-26 IN IN750/CAL/84A patent/IN163563B/en unknown
- 1984-10-31 ES ES537300A patent/ES8608532A1/es not_active Expired
- 1984-11-01 ZA ZA848541A patent/ZA848541B/xx unknown
- 1984-11-06 MX MX203300A patent/MX163574B/es unknown
- 1984-11-06 FR FR8416859A patent/FR2554346B1/fr not_active Expired
- 1984-11-06 GR GR80853A patent/GR80853B/el unknown
- 1984-11-07 AU AU35189/84A patent/AU569920B2/en not_active Ceased
- 1984-11-07 LU LU85633A patent/LU85633A1/fr unknown
- 1984-11-07 BE BE1/011131A patent/BE900994A/nl not_active IP Right Cessation
- 1984-11-07 PT PT79466A patent/PT79466B/pt not_active IP Right Cessation
- 1984-11-07 JP JP59235934A patent/JPS60132920A/ja active Granted
- 1984-11-07 NO NO844443A patent/NO844443L/no unknown
- 1984-11-07 CH CH5339/84A patent/CH662278A5/fr not_active IP Right Cessation
- 1984-11-08 KR KR1019840006985A patent/KR850003503A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES8608532A1 (es) | 1986-07-16 |
| FR2554346B1 (fr) | 1987-11-20 |
| EP0145209A3 (en) | 1986-11-26 |
| ES537300A0 (es) | 1986-07-16 |
| ZA848541B (en) | 1985-06-26 |
| IL73292A (en) | 1988-07-31 |
| IT1212896B (it) | 1989-11-30 |
| JPS60132920A (ja) | 1985-07-16 |
| NZ209974A (en) | 1987-02-20 |
| MX163574B (es) | 1992-06-02 |
| DE3480053D1 (en) | 1989-11-16 |
| GR80853B (en) | 1985-02-26 |
| DK160129B (da) | 1991-02-04 |
| EP0145209A2 (en) | 1985-06-19 |
| IN163563B (ko) | 1988-10-08 |
| IL73292A0 (en) | 1985-01-31 |
| ATE47035T1 (de) | 1989-10-15 |
| AU569920B2 (en) | 1988-02-25 |
| PT79466A (en) | 1984-12-01 |
| DK505584A (da) | 1985-05-09 |
| EP0145209B1 (en) | 1989-10-11 |
| BE900994A (nl) | 1985-05-07 |
| CH662278A5 (fr) | 1987-09-30 |
| PT79466B (en) | 1986-12-12 |
| LU85633A1 (fr) | 1985-06-04 |
| JPH0211570B2 (ko) | 1990-03-14 |
| FR2554346A1 (fr) | 1985-05-10 |
| NO844443L (no) | 1985-05-09 |
| AU3518984A (en) | 1985-05-16 |
| US4639437A (en) | 1987-01-27 |
| IT8349288A0 (it) | 1983-11-08 |
| DK160129C (da) | 1991-07-01 |
| DK505584D0 (da) | 1984-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR850003503A (ko) | 갱글리오사이드 및 그 유도체의 흡입투여 키트와 이에 적합한 약제 조성물 | |
| PT88944A (pt) | Processo para a preparacao de novos derivados de benzociclohepteno e de composicoes farmaceuticas que os contem | |
| EA199700267A1 (ru) | Применение фумагиллола и его производных для приготовления антиинфекционных интестинальных препаратов и фармацевтическая композиция на их основе | |
| IL75337A (en) | Polyenoic acids omega-substituted by a 4,5-dimethoxy-2-methyl-quinone or a 4,5-dimethoxy-2-methyl-phenyl group,process for the preparation thereof and pharmaceutical compositions containing the same | |
| AU639717B2 (en) | 24-homo vitamin d derivatives, process for their production and pharmaceutical preparations obtained therefrom | |
| MX9201014A (es) | Composicion farmaceutica para disminuir el nivel de colesterol en plasma. | |
| SE7707462L (sv) | Forfarande for framstellning av penicillansyraderivat | |
| ES2063186T3 (es) | Derivados ftalinida, composicion farmaceutica y uso. | |
| FR2649110B1 (fr) | Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| DE2967513D1 (en) | Imidazole derivatives, process for their preparation and pharmaceutical compositions containing them | |
| MX6526E (es) | Procedimiento para la preparacion de derivados 3-alil-7,8-dihidroxi-6-halogeno-1-(4-hidroxifenil)-2,3,4,5-tetrahidro-1h-3-benzazepina | |
| KR860001798A (ko) | 플라바논 유도체의 제조방법 | |
| BR9911274A (pt) | Derivados da artemisinina, seus processos de preparação e as composições farmacêuticas que os contêm | |
| DE69033183D1 (de) | Phosphozucker enthaltende pharmazeutische zubereitung | |
| AR246745A1 (es) | Procedimiento para preparar nuevos derivados de 1,4-di-desoxi-1,4-imino-d-arabinitol, sus isomeros opticos y geometricos y sus sales farmaceuticamente aceptables. | |
| ATE58837T1 (de) | Pharmazeutische zusammensetzungen zur verminderung der nebenwirkungen der anti-krebschemotherapie und erhoehung der immunitaet. | |
| KR880009975A (ko) | 화합물 | |
| ES8402819A1 (es) | Procedimiento para la produccion de una 3,3-dialquil-o 3,3-dialquileno-indolina. | |
| ES8301631A1 (es) | Un metodo para la preparacion de una formulacion farmaceutica de un antibiotico glicosidico o similar. | |
| IL41868A (en) | Pharmaceutical preparations containing d-penicillamine | |
| NO126529B (ko) | ||
| GB1416831A (en) | Dihydroxydiphenylmethane derivatives | |
| SE9002251L (sv) | Foerfarande foer framstaellning av vattenloeslig primycin och dess komponenter samt farmaceutiska kompositioner innehaallande dessa | |
| GB1337085A (en) | Aminoalkyl bis-4-chlorophenoxy acetates and process for their preparation | |
| FR2592653A1 (fr) | Derives de chromene, procede d'obtention et compositions pharmaceutiques. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |